DAsatinib DIscontinuation for 1st-Line treatment with Chronic Myelogenous Leukemia-Chronic Phase with One Year Complete Molecular Remission

Acronym

1st DADI-Trial

Scientific Title

DAsatinib DIscontinuation for 1st-Line treatment with Chronic Myelogenous Leukemia-Chronic Phase with One Year Complete Molecular Remission

Scientific Title:Acronym

1st DADI-Trial

Region

Japan

Condition

Condition

chronic myeloid leukemia

Classification by specialty

Medicine in general

Classification by malignancy

Malignancy

Genomic information

YES

Objectives

Narrative objectives1

The purpose of this study is molecular relapse free survival rate after discontinuation of dastinib in patients with 1st line treatment with Chronic Myelogenou Leukemia-Chronic Phase who have maintained complete molecular remission for at least 1 year.

We assessed LGL expansions, dose of dasatinib and time to CMR, total dose of dasatinib in last 12 months during CMR, metods and, sex and sokal risk group as potential prognostic factors for molecular relapse free survival.

1.Patients who have been treated by TKI except Dasatinib or Interferon.(except patients who have treated by Imatinib within 4 weeks as an ex-treatment.)
2. Concurrent malignancy other than CML
3.Women who are pregnant or breastfeeding
4.A serious uncontrolled medical disorder that would impair the ability of the subjects to receive protocol therapy